Stock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced

Stock Track

Sep 30

REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.

The primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.

Adding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1167520313"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167520313\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167520313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167520313","market":"nz","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced","media":"Stock Track","content":"<p>REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.</p>\n\n<p>The primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.</p>\n\n<p>Adding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 7.41% as Ophthalmology Drug Files for Approval and ESMO Presentations Announced\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-30 11:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.</p>\n\n<p>The primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.</p>\n\n<p>Adding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1167520313","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167520313","pubTimestamp":1759202540,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|REMEGEN飙升7.41%，眼科药物申报审批和ESMO演示公布","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.\nThe primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.\nAdding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}